Key facts
- This page summarizes Helen Sabzevari's Form 4 filing for Kinnate Biopharma Inc..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 05 Apr 2024, 16:55.
Helen Sabzevari - 03 Apr 2024 Form 4 Insider Report for Kinnate Biopharma Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 03 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Apr 2024, 16:55:16 UTC
- Prior SEC filing
- 25 Aug 2023
- Next SEC filing
- 09 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ James P. Reilly, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Helen Sabzevari filed Form 4 for Kinnate Biopharma Inc. on 05 Apr 2024.
Change
- Previous filing in this sequence was filed on 25 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KNTE
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -40,501
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,501
- Exercise price
- $24.38
- Footnotes
- F1
KNTE
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $3.48
- Footnotes
- F1
KNTE
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -20,250
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 03 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,250
- Exercise price
- $8.38
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Helen Sabzevari is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.